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ÖSSZEFOGLALÁS 
A pikkelysömör kezelésében használatos dithranol hatás-
mechanizmusa teljesen ma sem ismert. A betegség pato-
mechanizmusáhan az interleukin-8 és az interleukin-JO 
fontos szerepet játszik. A szerzők azt vizsgálták, hogy mi-
ként befolyásolja a dithranol az interleukin-8 és az inter-
leukin-10 termelést, valamint az interleukin-10 receptor 
kifejeződést humán keratinocitákon. Munkájuk során hu-
mán keratinocita (HaCaT) sejtekből 0,1-1 ug/ml dithranol 
kezelés után 2 és 4 órával az összes RNS-t izolálták. Az 
RNS reverz transzkripcióját (RT) követően polimeráz 
láncreakciót hajtottak végre a cDNS-en interleukin-8, in-
terleukin-10 és interleukin-10 receptor specifikus primer 
párokkal. Immunhisztokémiai vizsgálatokhoz a HaCaT 
sejteket humán interleukin-10 receptorellenes antitesttel 
inkubálták. Eredményeik szerint HaCaT sejtekben a dith-
ranol kezelés nem változtatta meg az igen magas interleu-
kin-8 mRNS-szintet, míg az interleukin-10 termelése PCR 
technikával nem volt kimutatható. Az interleukin-10 re-
ceptor esetében a dithranol koncentrációjától függően az 
mRNS emelkedését találták, amit immunhisztokémiai vizs-
gálat segítségével fehérjeszinten is igazoltak. Mivel az in-
terleukin-10 receptor a pikkelysömörös lézió keratinocitá-
inak felszínén csökkent mennyiségben van jelen, a dithra-
nol okozta receptormennyiség-növekedés része lehet a te-
rápiás hatásnak. 
Kulcsszavak: 
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A pikkelysömörre jellemző gyulladás és epidermális pro-
liferáció létrejöttében a stimuláló hatásoknak és a gátló 
mechanizmusok elégtelenségének jelentősége van. Az in-
terleukin-8 (IL-8) egy gyulladáskeltő citokin, melyet szá-
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SUMMARY 
Dithranol is highly effective in the treatment of psoriasis, 
however its mode of action is still not well known. Since in-
terleukin-8 and interleukin-10 are involved in the pathoge-
nesis of psoriasis, the aim of our study was to investigate the 
effect of dithranol on interleukin-S, interleukin-10 mRNA 
production and interleukin-10 receptor expression of kerati-
nocytes. Cultured HaCaT cells were treated with 0.1-1 
jtglml dithranol for 30 minutes. After 2 and 4 hours total 
cellular RNA isolated from HaCaT cells was reverse transc-
ribed (RT) to DNA which was subjected to polymerase cha-
in reaction (PCR) with specific primer pairs for interleukin-
8, interleukin-10 and interleukin-10 receptor. For immuno-
histochemistry cultured HaCaT cells were stained with a 
monoclonal antibody against the human interleukin-10 re-
ceptor. Our results showed that dithranol treatment did not 
change the highly elevated level of interleukin-8 mRNA of 
HaCaT cells and interleukin-10 mRNA signal with RT-PCR 
could not be detected in HaCaT cells. Depending on the 
concentration dithranol increased the mRNA production of 
interleukin-10 receptors in HaCaT cells. This dithranol in-
duced interleukin-10 receptor upregulation was also obser-
ved on the protein level using immunohistochemistry in a 
dose dependent way. Since the interleukin-10 receptor exp-
ression of keratinocytes in psoriatic lesional skin is downre-
gulated, the dithranol induced upregulation of the receptor 
might be involved in the therapeutic action of the drug. 
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mos sejttípus termel a bőrben, specifikus receptora (IL-
8R) a keratinociták felszínén is jelen van (19). A betegség 
patogenezisében fontos szerepe van az interleukin-8 (IL-
8) (46, 47) és receptora (44) megváltozott szabályozásá-
nak. Munkacsoportunk korábbi eredményei azt mutatták, 
hogy a különböző antipsoriatikus hatású szerek gátolják 
az IL-8 keratinocitákhoz kötődését (19, 24, 32) és befo-
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lyásol ják az IL-8 g é n , va l amin t az IL-8R expresszióját is 
(30, 44) . A p 5 3 m e n n y i s é g e a l acsonyabb a p ikke lysömö-
rös p lakkokban , s z i n t j e e m e l k e d i k az ant ipsoriat ikus hatá-
sú tacrol imus ( F K - 5 0 6 ) ha tására (30) . 
A gyu l l adásc sökken tő c i tok inek szerepéről még kevese t 
tudunk. A z in te r l euk in -10 ( IL-10) a gyul ladásos fo lyama-
tokat gátol ja . T e r m e l é s é t e lőször a T-he lper : (Th : ) sej tek-
ben írták le. ha tása a T-he lper , (Th , ) l imfoci ták t ípusos ci-
tokin vá laszának c s ö k k e n t é s e (12) . Ú j a b b e r edmények 
szerint az I L - 1 0 s z u b k u t á n a lka lmazása ant ipsoriat ikus 
hatású, mely ar ra utal , h o g y a p ikke lysömörös lézióban 
relatív IL-10 h i ány áll f e n n (1). 
A z IL-10 ha tásá t se j t fe l sz ín i receptor segí tségével fej t i 
ki ( IL-10R) . A z u tóbb i é v e k kutatásai t isztázták az IL-10R 
je lenlété t h u m á n ke ra t inoc i t ákon , és csökkent k i fe jeződé-
sét a p ikke ly sömörös l éz ióban (34). További v izsgála tok 
igazolták, hogy e p i d e r m á l i s se j tek fe lsz ínén az IL-10R ki-
fe jeződés t növel i az ant ipsor ia t ikus hatású D3-vi tamin, a 
calcipotr íol (31) é s s te ro id (34) kezelés . A p ikke lysömörös 
beteg keze lésében haszná la tos di thranol ha tásmechaniz-
m u s m a sem ismer t t e l j esen (23) . 
A spontán t r ansz fo rmá l t h u m á n kerat inoci ta sej tvonal 
(HaCaT) . me ly d i f f e r enc i á lódás szempont jábó l hasonló a 
normál kera t inoc i tákhoz e l fogadot t model l a hiperprol i fe-
ratív bő rbe tegségek in v i t ro t anu lmányozásában ( 5 , 4 1 ) . 
Jelen m u n k á n k b a n azt v izsgá l tuk , hogyan befolyásol ja a 
di thranol a H a C a T se j t ek IL -8 és IL-10 termelését , vala-
mint az IL-10 recep to r k i f e j eződésé t . 
Módszerek 
Sejlkulíűra 
A spontán transzformált humán HaCaT keratinocita sejtvonalat (a 
sejtekért köszönet dr. N. E. Fusenignek, Heidelberg, Németország) 
10%-os borjúszérum albuminnal (FCS), 100 U/nil penicillinnel és 
100 pg/ml streptomycinnel kiegészített (Gibco, Németország) Dul-
becco modified Eagle médiumban (DMEM) (Gibco, Németország) 
inkubáltuk 37 °C-on. 5% C02-t tartalmazó, 100%-os relatív páratar-
talmú termosztátban. 
Az IL-10 termelés vizsgálatához pozitív kontrollként a BCBL-1 
sejtvonalat használtuk (16) (a sejtekért köszönet dr. Gáspár Gábor-
nak). 
Dithranol kezelés 
A szubkonfluens HaCaT sejteket foszfát puffer (PBS) (Gibco, Német-
ország) mosás után 30 percig 0,1-1 pg/ml koncentrációjú dithranolt 
(Hermái Chemie, Reinbek, Németország) tartalmazó 0,5% FCS tartal-
mú DMEM oldatban 37 °C-on, 5% C02-t tartalmazó, 100%-os rela-
tív páratartalmú termosztátban inkubáltuk. A dithranolt közvetlenül 
felhasználás előtt acetonban oldottuk fel. Kontrollnak acetonnal kezelt 
és kezeletlenül hagyott HaCaT sejteket használtunk. 
RNS-izolálás és szemikvantitatív reverz transzkriptáz-polimeráz 
láncreakció (RT-PCR) 
A dithranol kezelt HaCaT sejteket PBS-mosás után 10% FCS tartal-
mú DMEM oldatban 37 °C-on, 5% C02-t tartalmazó, 100%-os rela-
tív páratartalmú termosztátban 75 cm:-es tenyésztő (Costar) edé-
nyekben 2 és 4 órán át inkubáltuk. Dithranol kezelt HaCaT sejtje-
inkből és a kezeletlen BCBL-1 sejtekből a TRIzol (Sigma) protokoll 
szerint az összes RNS-t kivontuk. Az RNS minőségét 1 %-os formal-
dehid-agaróz gélen etídiumbromid jelenlétében ellenőriztük. Az 
RNS koncentrációt spektrofotométer segítségével határoztuk meg. 
Az oligo dT15 primerek segítségével végrehajtott reverz transzkrip-
ciót (RT) követően polimeráz láncreakcióval (PCR) vizsgáltuk az 
IL-8, IL-10 és IL-10R mRNS-szintet. 
Primerek, szekvenciák 
IL-8 sense 
5' ATG ACTTCC AAG CTG GCC GTG GCT 3' 
IL-8 anti-sense 
5 'TCT CAG CCC TCT TCA AAA ACT TCT 3 ' 
IL-10 sense 
5' ATG CAC AGC TCA GCA CTG CTC TGT 3' 
IL-10 anti-sense 
5' CTT AAA GTC CTC CAG CAA GGA CTC CTTTAA 3' 
IL-10R sense 
5' ATG TGG GTG GCA CTG ACC TGT TCT 3' 
IL-10 anti-sense 
5' AGG GGG ATG CTA CTC CAT TTG TTG 3* 
A PCR reakciót a következőképpen végeztük: 
35 ciklus: 94 °C 60 másodperc, 59 °C 90 másodperc és 72 °C 90 
másodperc az IL-8 esetében, 35 ciklus: 94 °C 60 másodperc, 60 °C 
60 másodperc és 72 °C 60 másodperc az IL-10 esetében, és 35 cik-
lus: 94 °C 60 másodperc, 59 °C 45 másodperc és 72 °C 75 másod-
perc az IL-10R esetében. A PCR termékeket agaróz gélen etídiumb-
romid jelenlétében ultraibolya fény alatt tettük láthatóvá. Minden 
minta esetében párhuzamos B-aktin PCR reakciót hajtottunk végre, 
így tudtuk mennyiségileg is összehasonlítani a PCR reakciókban ka-
pott termékeket (szemikvantitatív RT-PCR). 
Immunhisztokémia 
Az IL-10 receptorellenes antitestet (R & D Systems) és az egér 
IgGl-t (DAKO) 0,1% Triton X-100-at és 0,5% borjúszérum albu-
mint tartalmazó foszfát pufferben hígítva 1 pg/ml koncentrációban 
használtuk. A speciális tárgylemezeken (NUNC slide chambers) te-
nyésztett HaCaT sejteket 2%-os paraformaldehidben fixáltuk 20 
percig 4 °C-on, majd 0,1% Triton X-100-at tartalmazó foszfát puf-
ferrel (TBST) mostuk. A tárgylemezeket 30 percig 43C-on humán 
IgG-vel inkubáltuk, hogy a sejtfelszíni Fc receptorokat blokkoljuk. 
Ezután mintáinkat az elsődleges antitestekkel (monoklonális, humán 
IL-10 receptorellenes) és a megfelelő kontroll antitestekkel (egér 
IgG 1) végzett éjszakán át tartó 4 °C-on történő inkubálás után a bio-
tinnal konjugált másodlagos antitestekkel 1 órán át inkubáltuk. A 
DAKO Strept ABC komplex kitjével (DAKO A/S, Dánia) streptavi-
din-biotin peroxidázt adtunk a rendszerhez, peroxidáz szubsztrát-
ként 3-amino-9-etilkarbazolt (AEC, Sigma) használtunk, majd a 
metszeteket hematoxilinnel festettük. 
Eredmények 
RT-PCR 
A z IL-8 mRNS-sz in t n e m változott 2 és 4 órával a dithra-
nol kezelést követően a kezelet len és az acetonos kontrol-
lokhoz viszonyí tva (1. ábra). 
A H a C a T sej tek IL-10 te rmelésének vizsgálatához pozi-
tív kontrol lként a B C B L - 1 se j tvonala t használ tuk. Ered-
ménye ink szerint H a C a T sej tek n e m termelnek IL-10-et . 
Min tá inkban csak a kis menny i ségben j e l en levő genomi 
IL -10 D N S - t detektál tuk, ami mére tben különbözöt t az 
R N S jelenléte esetén várt terméktől (2. ábra). 
A z IL-10 receptor m R N S - s z i n t e k a kontrol lokhoz ké-
pest a di thranol kezel t min tá inkban már 2 óra múlva a 
koncen t rác ió függd módon sz igni f ikáns emelkedés t mutat-
tak (3. ábra). 
Immunhisztokémia 
A h u m á n IL-10 receptor ra spec i f i kus monok loná l i s anti-
test tel pozi t ív fes tés t kap tunk a keze le t len H a C a T kerat i-
noc i ták fe l sz ínén . Technika i kon t ro l i j a ink esetén igen 
g y e n g e d i f f ú z c i top lazma fes tés t lá t tunk, ami arra utal , 
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1. ábra 
Dithranol kezelt HaCaT sejtek 
IL-8 mRNS-szint vizsgálata RT-PCR módszerrel 
1. sáv: molekulasúly marker, 2. sáv: pozitív kontroll, 
3. sáv: aceton kezelt sejtek 4h, 4. sáv: 1 pg/ml dithranol 
kezelt sejtek 4h, 5. sáv: 0,5 pg/ml dithranol kezelt 
sejtek 4h, 6. sáv: 0,1 pg/ml dithranol kezelt sejtek 4h, 
7. sáv: aceton kezelt sejtek 2h, 8. sáv: 1 pg/ml dithranol 
kezelt sejtek 2h, 9. sáv: 0,5 pg/ml dithranol kezelt 
sejtek 2h, 10. sáv: 0,1 pg/ml dithranol kezelt sejtek 2h 
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2. ábra 
Dithranol kezelt HaCaT sejtek 
IL-10 mRNS-szint vizsgálata RT-PCR módszerrel 
1. sáv: molekulasúly marker, 2. sáv: pozitív kontroll 
(BCBL-1 sejtvonal), 3. sáv: aceton kezelt sejtek 4h, 
4. sáv: 1 pg/ml dithranol kezelt sejtek 4h, 5. sáv: 0,5 pg/ml 
dithranol kezelt sejtek 4h, 6. sáv: 0,1 pg/ml dithranol 
kezelt sejtek 4h, 7. sáv: aceton kezelt sejtek 2h, 
8. sáv: 1 pg/ml dithranol kezelt sejtek 2h, 9. sáv: 0,5 pg/ml 
dithranol kezelt sejtek 2h, 10. sáv: 0,1 pg/ml dithranol 
kezelt sejtek 2h 
A nyíl: genomi IL-10 DNS-ről készült PCR-termék 
B nyíl: IL-10 mRNS-ről készült RT-PCR-termék 
hogy festésünk specifikus volt. Érdekes megfigyelés, 
hogy a kolóniák széli részén elhelyezkedő sejtek erősebb 
festést mutattak. Specifikus festődésű sejt jeinkben cito-
plazmatikus festődést is megfigyeltünk (4. ábra). A hu-
mán IL-10 receptorra specifikus monoklonális antitesttel 
dithranol kezelt HaCaT sejtek immunhisztokémiai vizs-
gálatát is elvégeztük. A sejtfelszínen a kezeletlen és csak 
aceton kezelt kontrollokhoz viszonyítva az IL-10 recep-
tor fokozott kifejeződése volt megfigyelhető. Ez a foko-
zott expresszió koncentrációfüggőnek bizonyult (5. áb-
ra). 
Megbeszélés 
Pikkelysömörös léziós bőrben az IL-8-termelés és IL-8 
receptor kifejeződés keratinociták esetében fokozott (6, 
32). Az IL-8 kemotaktikus hatással rendelkezik neutrofi-
lekre (29), T limfocitákra (26), bazofilekre (27) és kera-
tinocitákra (33). Fokozza a keratinocita proliferációt 
(49) és e sejtek HLA-DR kifejeződését indukálja (25). 
A kezeletlen HaCaT se j t ekhez v iszonyí to t t mRNS szint 
emelkedés a dithranol kezeit s e j t e k b e n denz i tomet r i á s 
m é r é s után. (2h) 
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A kezeletlen HaCaT se j t ekhez viszonyí tot t mRNS szint 
emelkedés a dithranol kezelt s e j t e k b e n denz i tomet r iás 
m é r é s után. (4h) 
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3. ábra 
(A) Dithranol kezelt HaCaT sejtek 
IL-10 receptor mRNS-szint vizsgálata RT-PCR módszerrel 
1. sáv: molekulasúly marker, 2. sáv: kezeletlen kontroll 
4h, 3. sáv: aceton kezelt sejtek 4h, 4. sáv: 0,5 pg/ml 
dithranol kezelt sejtek 4h, 5. sáv: 0,25 pg/ml dithranol 
kezelt sejtek 4h, 6. sáv: 0,1 pg/ml dithranol kezelt 
sejtek 4h, 7. sáv: kezeletlen kontroll 2h, 8. sáv: aceton 
kezelt sejtek 2h, 9. sáv: 0,5 pg/ml dithranol kezelt sejtek 
2h, 10. sáv: 0,25 pg/ml dithranol kezelt sejtek 2h, 11. sáv: 
0,1 pg/ml dithranol kezelt sejtek 2h 
(B) A kezeletlen HaCaT sejtekhez viszonyított 
mRNS-szint emelkedés a dithranol kezelt sejtekben 
denzitometriás mérés után (2h) 
(C) A kezeletlen HaCaT sejtekhez viszonyított 
mRNS-szint emelkedés a dithranol kezelt sejtekben 
denzitometriás mérés után (4h) 
Az IL-8 specifikus receptora segítségével fejti ki hatását 
(IL-8R), amelynek a kifejeződését az interleukin-1 (IL-
1) és tumor nekrózis faktor-alfa (TNF-a ) fokozza (20, 
21). Pikkelysömörös léziós bőrben az IL-8 mRNS 10-
szer nagyobb mennyiségben van jelen a betegség által 
nem érintett bőrterülethez képest (44). Munkacsoportunk 
korábbi eredményei arra utalnak, hogy különböző anti-
psoriatikus hatású szerek közül a cyclosporin, a calcitriol, 
a calcipotriol és a dithranol az IL-8 keratinocitákhoz va-
ló kötődését gátolja (19, 24, 32) míg a tacrolimus 
(FK-506) az IL-8 gén kifejeződését és az IL-8R expre-
szióját befolyásolja (30, 44). Egy másik igen fontos cito-
kin, az IL-10 a gyulladásos folyamatokat gátolja (1). 
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4. Áfera 
(A) A humán IL-10 receptorra specifikus monoklonális 
antitesttel pozitív festést kaptunk a kezeletlen HaCaT 
keratinociták felszínén 
(B) Technikai kontrolijaink esetén igen gyenge diffúz 
citoplazma festést láttunk, ami arra utal, hogy festésünk 
specifikus volt. 
Termelését először a T-helper2 (Th2) sejtekben írták le, 
hatása a T-helperl (Th l ) limfociták típusos citokin vála-
szának csökkentése (12). 
A Th2 sejteken kívül monociták/makrofágok, B-sejtek, 
eozinofilek és hízósejtek képesek IL-10 termelésre (7, 28, 
36, 45). Az emberi bőrben a legjelentősebb a makrofágok 
szerepe az IL-10 előállításában (17). Keratinociták IL-10 
termelésével kapcsolatban ellentmondásos irodalmi ada-
tok állnak rendelkezésre (10, 13, 15, 37, 38, 40, 48). Ered-
ményeink azt mutatták, hogy a HaCaT sejtek nem termel-
nek IL-10-et. Az IL-10 gátolja a monociták/makrofágok 
(7, 8, 11), dendritikus sejtek (35), Langerhans sejtek (4, 
9), és a keratinociták (2) gyulladáskeltő citokin termelését 
és antigén prezentálóképességét, valamint a keratinocita 
kultúrákban az interferon-g (IFNg) kiváltotta HLA-DR 
expressziót. és kismértékben csökkenti a keratinociták nö-
vekedési ütemét (34). Az IL-10 hatását specifikus recepto-
rán keresztül fejti ki, amely szerkezeti hasonlóságot mutat 
az IFNg receptorral (14). Korábbi tanulmányok igazolták, 
hogy pikkelysömörös lézióban az IL-10 receptor kifejező-
dése csökkent (34). 
A dithranol egy igen hatásos szer a pikkelysömör keze-
lésében, hatásmechanizmusát azonban még ma sem is-
V®7ftf 
5. ábra 
A humán IL-10 receptorra specifikus monoklonális 
antitesttel dithranol kezelt HaCaT sejtek 
immunhisztokémiai vizsgálatát is elvégeztük. 
A sejtfelszínen az IL-10 receptor fokozott kifejeződése 
volt megfigyelhető. Ez a fokozott expresszió 
koncentrációfüggőnek bizonyult 
(A) 0,1 pg/ml dithranol kezelt HaCaT sejtek 
(B) 0,25 pg/ml dithranol kezelt HaCaT sejtek 
merjük teljesen. A dithranol gátolja a polimorfonukleáris 
sejtek (neutrofilek) működését (43), és befolyásolja az 
arachidonsav metabolizmust (3, 42). Közvetlen gátló ha-
tással bír a keratinocita proliferációra (39). Epidermális 
sejtek bizonyos sejtfelszíni receptorainak kifejeződését is 
befolyásolja (18, 22). 
Eredményeink szerint a dithranol a HaCaT keratinoci-
ták IL-8 termelését nem befolyásolja. További vizsgálata-
ink azt mutatták, hogy a HaCaT sejtek nem termelnek IL-
10-et. Azonban a humán HaCaT keratinociták rendelkez-
nek IL-10 receptorral, és ezen sejtek in vitro dithranol ke-
zelése az IL-10 receptor kifejeződésének fokozását ered-
ményezi. Feltételezhető, hogy a dithranol antipsoriatikus 
hatásának része IL-10 receptor modulálása, melynek a 
pikkelysömör jövőbeni terápiájában jelentős szerepe le-
het. 
Köszönetnyilvánítás 
A munka az OTKA T-32496 és az ETT-T 05073/99 támogatásával 
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Abstract . Objective: Dithranol is highly effective in the 
treatment of psoriasis, however its mode of action is still not 
well known. Since interleukin-8 and interleukin-10 are in-
volved in the pathogenesis of psoriasis, the aim of our study 
was to investigate the effect of dithranol on interleukin-8, 
interleukin-10 mRNA production and interleukin-10 re-
ceptor expression of the HaCaT keratinocyte cell line which 
is commonly used in experiments examining the effects of 
therapeutic drugs on keratinocytes. 
Materials and Methods: Cultured HaCaT cells were treated 
with 0.1-0.5 pg/ml dithranol for 30 minutes. After 2 and 4 h 
total cellular RNA isolated from HaCaT cells was reverse 
transcribed (RT) to cDNA which was subjected to poly-
merase chain reaction (PCR) with specific primer pairs for 
interleukin-8, interleukin-10 and interleukin-10 receptor. For 
immunohistochemistry cultured HaCaT cells were stained 
with a monoclonal antibody against the human interleukin-
10 receptor. 
Results: Our results showed that dithranol treatment did not 
change the highly elevated level of interleukin-8 mRNA of 
HaCaT cells. Interleukin-10 mRNA signal with RT-PCR 
could not be detected in HaCaT cells. Depending on the con-
centration dithranol increased the mRNA production of 
interleukin-10 receptors in HaCaT cells. This dithranol in-
duced dose dependent upregulation of IL-10 receptors in 
HaCaT cells was also observed on the protein level using 
immunohistochemistry. 
Conclusions: Since the interleukin-10 receptor expression of 
keratinocytes in psoriatic lesional skin is downregulated, the 
dithranol induced upregulation of the receptor in our model 
system might help to reveal the therapeutic action of the 
drug. 
Key words: Interleukin-8 - lnterleukin-10 - Interleukin-10 
receptor - Psoriasis - Dithranol 
Correspondence to: Á. Farkas 
Introduction 
Psoriasis a common skin disease is characterized by inflam-
mation and abnormal epidermal proliferation. The highly 
elevated amounts of stimulatory signals and the failure of 
inhibitory mechanisms may cause these pathologic features. 
IL-8 a proinflammatory cytokine is produced by several cell 
types of the skin and receptors for IL-8 are also present on 
keratinocytes [1], An altered regulation for interleukin-8 
(IL-8) [2, 3] and its type I receptor (IL-8RA) [4] could be 
demonstrated in psoriasis. The IL-8/IL8R system is involved 
in the accumulation of inflammatory cells in psoriatic lesions 
and in keratinocyte proliferation [5]. Several antipsoriatic 
compounds inhibit the IL-8 binding to cultured keratinocytes 
[1, 6, 7] and affect the IL-8 gene and IL-8 receptor expres-
sion [4, 8], 
On the other hand, the antioncogene p53 is expressed at 
low levels in psoriatic plaques and can be significantly in-
duced by the antipsoriatic drug tacrolimus (FK-506) [8]. 
There is only limited knowledge about the role of anti-
inflammatory cytokines in psoriasis. Interleukin-10 (IL-10) a 
negative modulator of inflammatory processes was firstly 
described as cytokine synthesis inhibitory factor (CSIF) [9]. 
Recent studies showed that subcutaneous injection of IL-10 
has clinical efficiency in psoriasis [10]. The effects of IL-10 
are mediated by specific receptors (IL-lOR).We could earlier 
show the presence and functionality of the IL-10 receptor in 
human keratinocytes, its dramatic decreased expression in 
psoriatic epidermis [11] and the possibility of raising IL-10 
receptor transcript levels by the treatment of epidermal cells 
with antipsoriatic compounds such as vitamin D3, calcipo-
triol [12] and steroids [11], Dithranol is highly effective in 
the treatment of psoriasis, however its mode of action is still 
not well known [13]. 
The HaCaT cell line is widely used in experiments 
examining the effects of therapeutic drugs on keratinocyte 
physiology and studying keratinocyte proliferation and dif-
ferentation [14-17]. 
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In the present report we studied the IL-10 production of 
human H a C a T keratinocytes [18] and the effect of dithranol 
on the expression of IL-8 and IL-10 receptor genes in human 
H a C a T keratinocytes. 
Materials and methods 
Cell culture 
The spontaneously transformed human epidermal cell line HaCaT 
(kindly provided by Dr. N.E. Fusenig, Heidelberg, Germany) was cul-
tured in Dulbecco's Modification of Eagle's Medium (DMEM) (Gibco, 
Germany) containing 10% fetal calf serum (FCS) (Gibco, Germany). 
The cells were maintained at 37 °C in a humid 5% C02 atmosphere 
incubator. 
As a positive control for the IL-10 RT-PCR studies the BCBL-1 cell 
line (kindly provided by Dr. G. Gáspár, Szeged, Hungary) [19] was used. 
Dithranol treatment 
The subconfluent cells were washed with Phosphate Buffered Saline 
(PBS) (Gibco, Germany) under sterile conditions and were incubated 
for 30 min at 37 °C in a humid 5% C02 atmosphere incubator with 
increasing concentrations of dithranol (0.1-0.5 pg/ml) (Hermal Che-
mie, Reinbek, Germany) in DMEM containing 0.5% FCS. Dithranol 
was always freshly dissolved in acetone and used immediately. Control 
cells were treated with the solvent (acetone) only or left untreated. 
RNA extraction and semi-quantitative reverse transcriptase-
polymerase chain reaction (RT-PCR) 
Dithranol treated cells were then washed with PBS and were incubated 
in DMEM containing 10% FCS for 2 and 4 h at 37°C in a humid 5% 
C02 atmosphere incubator before isolating total cellular RNA ac-
cording to the TRIzol® (Sigma) protocol. The quality of the RNA was 
tested in 1 % formaldehyde-agarose gel stained with ethidium bromide 
(EtBr). The RNA concentration was measured using a spectrophoto-
meter. After reverse transcription (RT) with oligo (dT)„ primers, semi-
quantitative polymerase chain reaction (PCR) was performed with dilu-
tions of our primary RT reaction products (1:1; 1:2; 1:4; 1:8) to deter-
mine IL-8 and IL-10R mRNA levels. For our IL-10 mRNA studies we 
have performed qualitative RT-PCR without diluting the primary RT 
product. 
Primer sequences: 
IL-8 sense 
5' ATG ACT TCC AAG CTG GCC GTG GCT 3' 
IL-8 anti-sense 
5' TCT CAG CCC TCT TCA AAA ACT TCT C 3' 
IL-10 sense 
5' ATG CAC AGC TCA GCA CTG CTC TGT 3' 
IL-10 anti-sense 
5' CTT AAA GTC CTC CAG CAA GGA CTC CTT TAA 3' 
IL-10R sense 
5' ATG TGG GTG GCA CTG ACC TGT TCT 3' 
IL-10R anti-sense 
5' AGG GGG ATG CTA CTC CAT TTG TTG 3' 
/3-actin sense 
5' AGA GAT GGC CAC GGC TGC TT 3' 
/3-actin anti-sense 
5' ATT TGC GGT GGA CGA TGG AG 3' 
The following cycling times and temperatures were used to amplify 
IL-8, IL-10, IL-10R and /3-actin transcripts: 35 cycles of 94 °C for 60 s, 
59 °C for 90 s and 72 °C for 90 s for IL-8, 35 cycles of 94 °C for 60 s, 
60 °C for 60 s and 72 °C for 60 s for IL-10,35 cycles of 94 °C for 60 s, 
59 8C for 45 s and 72 °C for 75 s for IL-10R and 20 cycles of 94 °C for 
60 s, 55 °C for 120 s and 72 °C for 105 s for /3-actin. After PCR ampli-
fication the products were visualized by EtBr-stained agarose gel 
electrophoresis. Band intensities were monitored by densitometric scan-
ning, standardized against /3-actin signals from parallel reactions (semi-
quantitative RT-PCR). 
The identity of the RT-PCR products in the case of IL-8, IL-10 and 
/3-actin were confirmed by cloning and sequencing. The identity of the 
IL-10 receptor RT-PCR product was confirmed by direct sequencing. 
Immunohistochemistry 
Both anti-IL-10 receptor monoclonal antibody (R&D Systems), and 
mouse IgG| (DAKO) were diluted to a working concentration of 1 pg/ml 
inTris-buffered saline (Sigma), containing 0.1%Triton X-100 (Sigma) 
and 0.5% bovine serum albumin. HaCaT cells cultured on 8.6 cm2 
uncoated culture slides were fixed in 2% paraformaldehyde for 20 min 
at 4°C, and washed in Tris-buffered saline, containing 0.1% Triton X-
100 (TBST). Slides were then incubated for 30 min at 4 °C with human 
IgG (0.5 mg/ml, heat aggregated at 65 °C for 20 min.) (Jackson Im-
munoRcsearch Lab. Inc, West Baltimore Pike, USA) in order to block 
cell surface Fc receptors. Excess liquid was eliminated without wash-
ing, and the slides were incubated overnight at 4°C with anti-IL-10 
receptor monoclonal antibody and negative control reagent (mouse 
IgG,), respectively. The antigen-antibody reaction was revealed by 
using a StreptABComplex Duet (mouse and rabbit) Reagent Set 
(DAKO). Briefly, the slides were incubated for 1 h at room temperature 
with the biotin-labeled second antibody (goat anti-mouse/rabbit Ig). 
After washing, avidin-HRP was added and the incubation was per-
formed in similar conditions as described for the second antibody. The 
peroxidase was developed with 3-amino-9-ethyl-carbazol (AEC Sig-
ma). Finally, the slides were washed in tap water, counterstained with 
hematoxylin, rewashed and mounted in DAKO Glycergel® aqeous 
mounting medium (DAKO). 
Results 
RT-PCR 
The expression of the IL-8, IL-10 and IL-10 receptor 
(IL-10R) gene was studied in H a C a T cells using semi-quan-
titative RT-PCR. A housekeeping gene /?-actin was used as an 
internal control. T h e /3-actin RT-PCR signals were constant in 
all our samples (Fig. 1). The IL-8 m R N A levels did not 
change af ter 2 or 4 h of dithranol t reatment compared to the 
untreated or acetone treated cells when RT-PCR was carried 
out with several dilutions of our pr imary RT reaction pro-
ducts (1:1; 1 :2; 1 :4; 1 :8 ) (Fig. 2). To study the IL-10 
production of H a C a T cells we used the BCBL-1 cell line 
(kindly provided by G. Gáspár) as a positive control. We 
could not demonstrate the IL-10 production of H a C a T cells. 
We could only detect the small amount of genomic D N A in 
our R N A samples di f fer ing in size f rom the product orig-
inating f rom the IL-10 m R N A (Fig. 3). T h e IL-10R m R N A 
levels were significantly elevated already af ter 2 h in the 
dithranol treated cells compared to the controls when RT-
P C R was carried out wi th several dilutions of our pr imary RT 
reaction products (1 :1 ; 1 :2 ; 1 :4; 1:8) . W h e n the pr imary RT 
product was used at the dilution of 1:8 we could not dectect 
any P C R signal. The induction of the IL-10R gene was dose 
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Fig. 1. RT-PCR analysis of /3-aktin expression in HaCaT cells treated 
with dithranol. Lane 1: untreated control 2 h, lane 2: acetone treated 
cells 2 h, lane 3: 0,1 pg/ml dithranol treated cells 2 h, lane 4: 0,25 pg/ml 
dithranol treated cells 2 h, lane 5: 0,5 pg/ml dithranol treated cells 2 h, 
lane 6: untreated control 4 h, lane 7: acetone treated cells 4 h, lane 8: 
0,1 pg/ml dithranol treated cells 4 h, lane 9: 0,25 pg/ml dithranol treated 
cells 4 h, lane 10: 0,5 pg/ml dithranol treated cells 4 h 
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Fig. 2. RT-PCR analysis of IL-8 expression in HaCaT cells treated with 
dithranol. Lane l: untreated control 2 h, lane 2: acetone treated cells 2 h, 
lane 3: 0,I pg/ml dithranol treated cells 2 h, lane 4: 0,25 pg/ml dithra-
nol treated cells 2 h, lane 5: 0,5 pg/ml dithranol treated cells 2 h, 
lane 6: untreated control 4 h, lane 7: acetone treated cells 4 h, lane 8: 
0,1 pg/ml dithranol treated cells 4 h, lane 9: 0,25 pg/ml dithranol 
treated cells 4 h, lane 10: 0,5 pg/ml dithranol treated cells 4 h. Arrow 
(1): undiluted primary RT product RT-PCR, Arrow (2): RT-PCR with 
1:2 dilution of primary RT product. Arrow (3): RT-PCR with 1:4 dilu-
tion of primary RT product, Arrow (4): RT-PCR with 1:8 dilution of 
primary RT product. 
Fig. 3. RT-PCR analysis of IL-10 expression in HaCaT cells treated 
with dithranol. Lane 1: molecular weight marker, lane 2: positive con-
trol, (BCBL-1 cell line), lane 3: untreated control 2 h, lane 4: acetone 
treated cells 2 h, lane 5: 0,1 pg/ml dithranol treated cells 2 h, lane 6: 
0,5 pg/ml dithranol treated cells 2 h, lane 7: untreated control 4 h, lane 
8: acetone treated cells 4 h, lane 9: 0,1 pg/ml dithranol treated cells 4 h, 
lane 10: 0,5 pg/ml dithranol treated cells 4 h. Arrow A: PCR product 
from genomic IL-10 DNA in the RNA samples. Arrow B: RT-PCR 
product from IL-10 mRNA. 
dependent reaching its m a x i m u m at 0,25 p g / m l dithranol 
concentrat ion (Fig. 4). 
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Fig. 4. (A) RT-PCR analysis of IL-10R expression in HaCaT cells treat-
ed with dithranol. Lane 1: untreated control 2 h, lane 2: acetone treated 
cells 2 h, lane 3: 0,1 pg/ml dithranol treated cells 2 h, lane 4: 0,25 pg/ml 
dithranol treated cells 2 h, lane 5: 0,5 pg/ml dithranol treated cells 2 h, 
lane 6: untreated control 4 h, lane 7: acetone treated cells 4 h, lane 8: 0,1 
pg/ml dithranol treated cells 4 h, lane 9: 0,25 pg/ml dithranol treated 
cells 4 h, lane 10: 0,5 pg/ml dithranol treated cells 4 h. Arrow (1): un-
diluted primary RT product RT-PCR, Arrow (2): RT-PCR with 1:2 dilu-
tion of primary RT product, Arrow (3): RT-PCR with 1:4 dilution of 
primary RT product. (B) Integrated peak areas after densitometric sig-
nals plotted as "fold induction" in comparison to unterated cells after 
2 h (undiluted primary RT product RT-PCR). (C) Integrated peak areas 
after densitometric signals plotted as "fold induction" in comparison to 
unterated cells after 4 h (undiluted primary RT product RT-PCR). 
Immunohistochemistry 
Untreated cultured H a C a T cells were s tained with a mono-
clonal ant ibody against h u m a n IL-10 receptor. Relat ive to the 
isotype control the ant ibody clearly stained the cells. A clear 
membrane localisation was apparent and interestingly it 
seemed that cells local ised at the edges of the colonies 
showed stronger expression. Bes ide the m e m b r a n e staining 
there was some cytoplasmic staining as well (Fig. 5). We have 
also pe r fo rmed immunocy tochemis t ry on cultured H a C a T 
cells that were treated with di thranol . At all concentrat ions 
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Fig. 5. Immunocytochemistry with a monoclonal antibody against 
human IL-10 receptor on cultured HaCaT cells. (A) HaCaT cells with 
clear membrane localization of the human IL-10 receptor. (B) Isotype 
control. 
Fig. 6. Immunocytochemistry with a monoclonal antibody against 
human IL-10 receptor on cultured HaCaT cells that were treated with 
dithranol. (A) 0,1 pg/ml dithranol treated HaCaT cells. (B) 0,25 pg/ml 
dithranol treated HaCaT cells. 
tested (0.1-0.5 pg/ml) the dithranol clearly had a cytostatic 
effect on the cells, that was apparent by the size of the cell 
colonies relative to the untreated control cultures. With the 
monoclonal antibody staining there was a slight indication 
for enhanced expression of IL-10 receptor, predominantly on 
the cell membrane in the dithranol treated cultures, and this 
difference seemed to depend on the concentration (Fig. 6). 
Discussion 
In psoriatic lesional skin the genes for proinflammatory fac-
tors as the IL8/IL-8 receptor system are overexpressed [7], 
IL-8 is chemotactic for neutrophils [20], T lymphocytes [21], 
basophils [22] and keratinocytes [23], it stimulates neutro-
phil degradation and oxidative burst activity [24], It pro-
motes keratinocyte proliferation [25] and induces HLA-DR 
expression in keratinocytes [26]. The effects of IL-8 on kera-
tinocytes are mediated through specific receptors, which 
may be upregulated by interleukin-1 (IL-1) and tumor necro-
sis factor alpha (TNF-a) [27, 28]. In lesional psoriatic epi-
dermis, IL-8 receptor specific mRNA level was found to be 
10-fold higher compared with the uninvolved skin [18]. Our 
earlier results showed that several antipsoriatic compounds 
as cyclosporine, calcitriol, calcipotriol and dithranol have 
inhibitory effects on IL-8 binding to cultured keratinocytes 
[1 ,6 , 7]. The IL8/IL8R system can be downregulated when 
epidermal cells are treated with the antipsoriatic drug tacro-
limus (FK-506) in vitro [4, 8], 
Another cytokine IL-10 has gained increasing impor-
tance as a negative modulator of inflammatory processes 
[10]. IL-10 was firstly described in T-helper2 (Th2) cells and 
characterized by its ability to inhibit the typical cytokine re-
sponse ofT-helper, (Th,) lymphocytes [9], Besides Th2 cells 
monocytes/macrophages, B cells, eosinophils and mast cells 
are able to produce IL-10 [29-32] , In human skin macro-
phages are the main source of IL-10 [33]. The IL-10 syn-
thesis of keratinocytes is controversally discussed in the 
literature [34-40], Our present studies suggest that HaCaT 
cells are not capable of producing IL -10. 
IL-10 suppresses proinflammatory cytokine production 
and antigen-presenting capacity of monocytes/macrophages 
[29, 41, 42], dendritic cells [43], Langerhans cells [44, 45] 
and keratinocytes [46]. 
We found earlier that in cultured keratinocytes IFN-y 
induced HLA-DR expression is inhibited by IL-10. It has a 
moderate but statistically significant and dose dependent 
inhibitory effect on the keratinocyte growth rate [11]. 
48 Á. Farkas et al. Inflamm, res. 
The effect of IL-10 is mediated through its specif ic re-
ceptor (IL-10R), which shares structural homologies with the 
interferon-gamma ( IFN-y) receptor [47]. Previous studies 
showed that IL-10R expression is decreased in psoriatic epi-
dermis [11]. 
Dithranol is a highly effect ive antipsoriatic compound. Its 
mode of action is still not completely understood. Dithranol 
inhibits polymorphonuclear leukocyte ( P M N ) funct ion [48] 
and modulates the arachidinoc acid metabol ism [49, 50]. It 
has a direct inhibitory effect on keratinocyte proliferation 
[51]. It is also capable of modula t ing cell surface receptors of 
epidermal cells [52, 53]. 
Our results show that dithranol does not act by regulating 
the IL-8 production of human cultured H a C a T keratinocytes. 
We could show that H a C a T cells are not capable of producing 
IL-10. 
In the present work we could demonstra te that H a C a T 
keratinocytes have IL-10 receptors and these cells in vitro 
respond to the treatment with the antipsoriatic drug dithranol 
by the induction of the IL-10 receptor gene. 
Since the IL-10 receptor gene is downregulated in psori-
atic epidermis [11] the pharmacological modulat ion of the 
receptor in our model system [ 1 4 - 1 7 ] may be an important 
target in the future for the therapy of psoriasis. 
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CD3+CD56+ NK T cells are significantly decreased in the peripheral blood 
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SUMMARY 
Psoriasis is a chronic, inflammatory, hyperproliferative skin disease, in which autoimmunity plays a great 
role. Natural killer T cells (NK T cells), are suggested to be involved in the pathogenesis of different 
autoimmune diseases. To examine the involvement of CD3*CD56* NK T cells in the pathogenesis of 
psoriasis, we investigated the lymphocyte subpopulations obtained from blood samples of psoriatic 
patients before and after treatment, and of healthy controls, using two-colour flow cytometry. We found 
no significant differences between total T cells, total B cells, T helper cells, T cytotoxic cells and NK 
cells in patients with psoriasis before and after treatment and in controls. Increased percentage of 
memory T cells and decreased percentage of naive T cells was detected in psoriatic patients compared 
to controls, but these changes were not statistically significant. The CD3*CD56* cells of psoriatic patients 
were significantly decreased relative to controls. The percentage of CD3+CD56+ cells increased after 
different antipsoriatic therapies, but remained significantly lower than those found in controls. 
CD3+CD56+ cells of healthy controls were capable of rapid activation, while in psoriatic patients acti-
vated NK T cells were almost absent. The decrease in the number of CD3+CD56+ cells may represent 
an intrinsic characteristic feature of patients with psoriasis, which is supported by the fact that after 
treatment NK T cells do not reach the values found in controls. In conclusion our results suggest that 
CD3+CD56f NK T cells could be actively involved in the development of Th 1 mediated autoimmune 
diseases. 
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INTRODUCTION 
Although the pathogenesis of psoriasis is not yet clear, there are 
characteristic features of the disease which suggest an immuno-
logical mediated process. Several direct and indirect evidences 
suggest thai T cells play a crucial role in the pathogenesis of 
psoriasis [1.-7]. The presence of T helper cells, that secrete type 1 
cytokines (IFN-y, 1L-2, TNF-a). was demonstrated in psoriatic 
skin lesions [8-13]. A type 1 differentiation bias was also observed 
in circulating blood T cells of psoriatic patients [14]. The existence 
of an imbalance between Thl and Th2 cells in psoriasis was sup-
ported further by findings which demonstrated that IL-10 was 
decreased in psoriatic lesions [15]. Moreover, during antipsoriatic 
therapy an increase in IL-10 mRNA expression was observed in 
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peripheral blood mononuclear cells [16]. IL-10 therapy given 
either intralesionally or subcutaneously resulted in marked reduc-
tion of psoriatic lesions [16,17]. These data suggest that psoriasis 
is an inflammatory Thl mediated autoimmune disorder, but the 
triggering autoantigens arc still not identified. 
Although the factors that induce the imbalance between 
Thl and Th2 cells in psoriasis are unknown, a possible role could 
be attributed to natural killer T cells (NK T cells) [1.8]. NK T 
cells are a heterogeneous T cell population characterized by the 
co-expression of a/3 or ySTCRs and various NK receptors, includ-
ing CD16, CD56, CD161, CD94, CD158a and CD158b [19-21], 
NK T cells have the ability to rapidly secrete large amounts 
of cytokines following activation [22-24]. NK T cell clones 
secrete type 1, type 2 or both types of cytokines, which could 
influence the differentiation of ThO cells towards Thl or Th2 
cells [25,26]. CD3XD56* cells represent one of the NK T cell 
populations. 
The number of CD3+CD56+ NK T cells has been shown to be 
significantly decreased in the peripheral blood of patients with 
176 © 2002 Blackwell Science 
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rheumatoid arthritis, another Thl mediated autoimmune disease 
[27]. 
In the present study we determined the number of 
CD3*CD564 NK T cells in the peripheral blood of patients with 
psoriasis (before and after treatment) and in healthy controls. 
Other lymphocyte subpopulations (total T cells, T helper cells, T 
cytotoxic cells, T memory cells, T naive cells, B lymphocytes and 
NK cells) were also analysed and compared in psoriatic patients 
and healthy volunteers. 
Our results show that CD3'CD56+ NK T cells are significantly 
decreased in the peripheral blood of patients with psoriasis rela-
tive to Ihe healthy controls. This finding is discussed in relation 
with the development of a type 1 immune response in psoriasis. 
PATIENTS AND METHODS 
Patients' profile 
Peripheral blood samples of 15 patients with psoriasis (one 
crythrodcrmic, two guttatc type and 12 chronic plaque psoriasis) 
were obtained with informed consent for use in this study. The 
Ethical Committee of the University of Szeged, Hungary 
approved this investigation. Blood samples were collected before 
and after treatment from all patients. The patients' characteri-
stics are presented in Table 1. Therapeutic modalities included 
monotherapy and combined therapeutic regimens (Tablc2). The 
second blood sample was taken at the time when the applied 
treatment regimen had been completed. At this time the major-
ity of patients was symptom-free or had minimal skin changes 
(PAS1 < 4). 
The control group consisted of 12 healthy hospital employees 
(seven females and five males), aged 37-08 ± 7-21 years with 
informed consent for use in the study. In the control group 
nobody took any medication and nobody suffered from any 
known acute or chronic disease. 
Reagents 
Anti-CD3 FITC. anti-CD3 PE (clone UCHT1), anti-CD19 PE 
(clone HD37), anti-CD4 FITC (clone MT310), anti-CD8 PE, anti-
CD8 FITC (clone DK 25). anti-CD25 FITC (clone ACT-1) and 
isotypc-matched labelled mouse immunoglobulins were obtained 
from DAKO (Copenhagen, Denmark), anti-CD56 FITC (clone 
NKH-1), anti-CD45RA PE (clone F8-11-13) were obtained from 
Serotec (Oxford, UK). anti-CD4 FITC (clone SK3), anti-CD56 
PE (MY31) from Becton-Dickinson (San Jose, CA. USA) and 
anli-CD45RO FITC (clone UCHL1) was obtained from 
Immunotech (Beckman Coulter, Fullerton, CA, USA). 
Immunostaining and flow cytometry 
Peripheral blood, anticoagulated with EDTA, was collected. Each 
blood sample (50/(l) was stained with two monoclonal antibodies, 
one conjugated with FITC and the other with PE (10/tl from 
each) at room temperature, in the dark for 20min Erythrocytes 
were lysed with FACS Lysing Solution (Becton Dickinson San 
Jose, CA, USA). After two washes with PBS the cells were resus-
pended in PBS for immediate analyses or were fixed with 2% 
paraformaldehyde for overnight storage before analyses. Two-
colour flow cytometry was performed by using a FACSCalibur 
cytomctcr and the data were analysed using Cell Quest software 
(Becton Dickinson. San Jose, CA. USA). In each stain 30000 
events were acquired. 
Isolation and stimulation of T cells from peripheral blood 
Mononuclear cells (PBMC) were isolated from peripheral venous 
blood samples of psoriatic patients and healthy controls by 
Ficoll-Hypaque density gradient centrifugation (Biotech Inc, 
Piscataway, NJ, USA). PBMC were recovered at the interface and 
washed in PBS supplemented with 2% fetal calf serum (FCS). T 
cells were isolated by positive selection using uniform magnetiz-
able polystyrene beads coated with monoclonal antibodies spe-
cific for CD3 (Dynabeads M-450CD3 from Dynal, Oslo, Norway) 
and a magnetic particle separator (Dynal MPC, from Dynal, Oslo, 
Norway) following the protocol provided by the manufacturer. 
Briefly, PBMC were incubated with CD3 monoclonal antibody 
coated magnetic beads (bead:cell ratio 5:1, Dynabeads concen-
tration 1 x 107/ml) for 6 h in RPMI 1640 culture medium supple-
mented with 10% FCS, at 37°C in a humid 5% C02 incubator. 
After the incubation time Dynabeads were detached from the 
cells by pipetting the cell suspension 10 times through an auto-
mated pipette. The beads were than removed from the cell sus-
pension using a Dynal MPC. The beads attached to the tube wall 
while the cells remained in the suspension. This isolation proce-
dure through the CD3 binding results in stimulation of the CD3* 
cells [28]. Hie isolated and stimulated cells were then analysed by 
two-colour flow cytometry, using monoclonal antibodies for 
Table 2. Treatment regimens used in the study 
Treatment Number of patients 
Dithranol! 6 
PUVA* 6 
Dithranol + PUVA! 1 
Dithranol + narrowband ultraviolet B (311 nm)§ 1 
Re-PUVAl 1 
Table 1. Patient profile 
Sex (male: female) 12:3* 
Age (years) 42-35 ± 14-32 
Age of onset (years) 25-7 ± 10-38! 
Disease duration (years) 16-7 ± 9-21 
Psoriasis type (chronic: eruptive) 13:2 
PASI score 18-77 ± 12-25 
Family history (positive: negative) 6 : 9 
(20-67)! 
(9-45) 
(3-37) 
(6-54) 
•Number of patients; !mean ± s.d.; frange. 
tDilhranol treatment was used in slowly increasing concentrations 
starting with 0-5% up to 8% depending on the induced erythema. 'Ora l 
8-methoxypsoralcn + UVA (four times a week) was administered from I 
J/cm2 up 5J/cm2 depending on the induced erythema. fDithranol treat-
ment with slowly increasing concentrations starting with 0-5% up to 8% 
was combined with oral 8-melhoxypsoralen + UVA (four limes a week) 
from IJ/cm2 up 5 J/cm2 depending on the induccd erythema. §Dithranol 
treatment with slowly increasing concentrations starting with 0-5% up to 
8% was combined with narrowband ultraviolet B from 0-2 J/cm2 up to 
2-2J/cm2 (five times a week) depending on the induced erythema. lOra l 
acitretin (0-5 mg/kg body wt) + oral 8-melhoxypsoralen + UVA (four times 
a week) from l J / cn r up 5 J/cm2 was administered depending on the 
induced erythema. 
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detection of CD56, CD25, CD4 and CD8. After 6h of anti-CD3 
antibody stimulation, the CD3 antigen was transiently down-reg-
ulated. By growing the cells for further 24 h in culture medium 
the CD3 antigen was reexpressed on the cell surface, and could 
be detected using FITC conjugated CD3 antibodies. Vitality of 
isolated cells was tested by trypan blue exclusion. 
Statistical analysis 
Statistical analysis of the data was made by ANOVA, Pearson 
correlation test and Spearman's rank order correlation test. For 
significant ANOVA values, groups were compared by Tukey's 
post hoc test for multiple comparisons with unequal cell size. A 
probability level of 0-05 was accepted as indicating significant 
differences. 
RESULTS 
Analyses of lymphocyte subsets 
The lymphocyte subsets in patients with psoriasis before treat-
ment and in healthy controls were analysed. The percentage of 
CD3*CD56* NK T cells was significantly decreased in the periph-
eral blood of patients with psoriasis before treatment compared 
with healthy controls (1-79 ± 107% in patients versus 5-22 ± 
1-74% in controls, P < 0 0001) (Table3). Representative flow cyto-
metric analyses show CD3'CD56+ NK T cells in a patient before 
treatment (0,78%) (Fig. lb) versus in a healthy control (6-28%) 
(Fig. la). The absolute number of circulating CD3*CD56+ NK T 
cells was also significantly lower in psoriatic patients before treat-
ment than the values found in healthy controls (29-43 ± 17-12 p\ 
in psoriasis before treatment versus 120-15 ± 45-35 p\ in controls, 
P < 0-0001). Memory T cells (CD3'CD45RCT) represented a 
larger (35-36 ± 9-38% in patients versus 27-21 ± 7-34% in controls) 
and naive T cells (CD3*CD45RA+) a smaller population (37-71 ± 
8-34% in patients versus 45-00 ± 7-19%) in the peripheral blood 
of patients relative to controls; however, these differences did not 
reach statistical significance. Similarly, a slight but statistically not 
significant increase in the proportion of helper CD4+ T helper 
cells was observed in patients with psoriasis (44-52 ± 9-05% in 
patients versus 38-97 ± 5-66% in controls P > 0-05). There was no 
difference in the percentages of B lymphocytes, conventional NK 
cells (CD3"CD56+), total T cells and T cytotoxic CD8+ cells 
between the two groups (Table 3). 
Table 3. Percentage of lymphocyte subsets (mean ± s.d.) in peripheral 
blood of patients with psoriasis before treatment, after treatment and of 
healthy controls 
Healthy 
Psoriasis before Psoriasis after controls 
treatment (%) treatment (%) (%) 
CD3' 72-46 ± 8-59 70-04 ± 8-59 70-78 ±4-71 
CD 19' II-24 ±4-87 11-5 ±5-41 13-97 ±4-63 
CD3*CD4* 44-52 ±9-05 42-54 ± 8-22 38-97 ± 5-66 
CD3*CD8* 27-12 ±8-21 26-39 ± 7-18 28-95 ±7-43 
CD3'CD56' 1-79 ±1-07 2-68 ± 1-04 5-22 ±1-74 
CD3-CD56' 10-20 ± 5-69 12-47 ± 6-98 10-30 ± 4-7 
CD3*CD45RA* 37-71 ± 8-34 37-90 ± 8-60 45-00 ± 7 1 9 
CD3+CD45RO* 35-36 ±9-38 35-13 ±9-87 27-21 ± 7-34 
Comparing the lymphocyte subsets of patients with psoriasis 
before and after treatment, the only lymphocyte population in 
which changes were statistically significant was the NK T 
(CD3*CD56*) subset. Both the percentage and the absolute cell 
number of NK T cells were significantly increased in the periph-
eral blood of patients with psoriasis after treatment (2-68 ± 1 -04%, 
29-43 ± 17-12/il versus 1-79 ± 1-07%, 58-95 ± 31-56pl, P < 0-001), 
but did not reach the values found in healthy controls (Table 3). 
A representative flow cytometric analysis shows the comparison 
of CD3*CD56* NK T cells in a patient before treatment (0-78%) 
(Fig. lb) versus in a patient after treatment (3-04%) (Fig. lc). 
We found no statistically significant changes in the other lym-
phocyte subsets (Table 3). The antipsoriatic treatments used in 
this study had no effect on the number of memory and naive T 
cells (Table 3). 
After treatment the absolute cell number of CD3'CD56* NK 
T cells remained significantly decreased in patients with psoriasis 
compared to healthy controls (58-95 ± 31-56pi in patients after 
treatment versus 120-15 ± 45-35 pi in controls, P < 0-001). The same 
was observed when the percentage of NK T cells among lym-
phocytes was analysed in peripheral blood samples (2-68 ± L-04% 
in patients versus 5-22 ± 1-74% in controls, P < 0-001) (Table 3). 
Representative flow cytometric analyses show CD3*CD56* NK T 
cells in a patient after treatment (3-04%) (Fig. lc) versus in a 
healthy control (6-28%) (Fig. la). Memory T cells remained ele-
vated (35-13 ± 9-87% in patients versus 27-21 + 7-34% in controls) 
and naive T cells were decreased in the psoriasis group compared 
to healthy controls (37-90 ± 8-60% in patients versus 45-00 ± 
7-19% in controls) (Table 3), without reaching statistical signifi-
cance. Similarly, the number of T helper cells showed a slight, sta-
tistically not significant elevation in treated patients compared to 
controls (42-54 ± 8-22% in patients versus 38-97 ± 5-66% in con-
trols P > 0-05) (Table 3). No difference between the two groups 
was found regarding B lymphocytes. NK cells, total T cells and 
cytotoxic T cells (Table 3). 
CD3*CD56* NK T cells and patients' profile 
To determine whether the number or the percentage of 
CD3*CD56+ NK T cells in patients with psoriasis shows any cor-
relation with age, PASI score and disease duration the appropi-
ate correlation test has been applied. The analysis of the possible 
correlation of NKT cells with age was also performed in healthy 
controls. Statistical analyses of our data showed a slight, but 
significant direct correlation between NK T cells and the age of 
controls (r, = +0-39). In contrast in psoriatic patients a slight, 
but statistically significant inverse correlation (r2 = -0-31) was 
detected (data not shown). We observed that patients with a long-
term history of frequent relapses, who did not respond well to 
treatment, had the lowest NKT cell counts. In these patients the 
recovery of NK T cells following therapy was slower and gener-
ally poor. However. CD3+CD56+ cells showed no correlation with 
PASI score and disease duration (data not shown). 
Stimulation of peripheral blood T cells with anti-CD3 
monoclonal antibodies 
To examine the activation status of CD3*CD56* NK T cells, we 
separated T cells from the peripheral blood of healthy controls 
and of patients with psoriasis. These T cells were stimulated for 
6h using anti-CD3 monoclonal antibodies, and then flow cyto-
metric analysis was performed. On the FSC/SSC dot-plot of sep-
arated and stimulated T cells obtained from healthy controls a 
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Fig. 1. Representat ive dot-plot d iagrams of per ipheral blood cells stained with PE conjugated an t i -CD3 monoclonal ant ibodies and PE 
conjugated ant i -CD56 monoclonal antibodies. CD3 'CD56 4 NK T cells in a healthy control (a), in a patient with psoriasis before t reatment 
(b) and in the same patient af ter t rea tment (c) are in the upper-right quadrants of each dot-plot diagrams. CD3*CD56* NK T cells are sig-
nificantly decreased in the peripheral blood of pat ients with psoriasis (b, 0-78%), the percentage of these cells increases af ter therapy (c. 
3 04%) , but remains significantly lower than in healthy controls (a, 6-28%). 
distinct cell population was recognized, which was not present as 
a distinct population on the dot-plot of unstimulated CD3* T cells 
(Fig. 2). These cells showed a marked granulated pattern. Analy-
sis of stimulated T cells was performed by using two gates: R1 for 
these granulated cells and R2 for the other cells. All the granu-
lated cells (gate Rl) expressed the surface molecule CD56, but 
only a minority of the other cells (gate R2) expressed this mole-
cule (Fig. 3). Tit us the granulated cells were NK T (CD3"CD56+) 
cells. More than half of NK T cells (gate R l ) expressed the CD4 
marker (71-25%), while very few of the less granulated 
CD3*CD56* NK T cells (gate R2) were CD4* (0-58%) (Fig. 3). 
The CDS molecule was expressed by more than half of the less 
granulated CD3+CD56+ NK T cells (gate R2) and by about one-
third of the granulated NK T cells (gate R l ) (Fig. 4). The low 
affinity receptor for 1L-2, an early activation marker for T cells, 
was detected with an anti-CD25 FITC labelled monoclonal anti-
body. Almost all the granulated NK T cells (gate R l ) expressed 
CD25 molecules (93-2%), indicating that they were activated 
cells. Among the less granulated cell population (gate R2) only 
59-65% of the cells expressed the low affinity IL-2 receptor (data 
not shown). After analysing the separated and stimulated T cells 
collected from patients with psoriasis we found that CD56* T cells 
with marked granulated pattern were almost absent. Scattered 
CD56* T cells were present between the cells with normal gran-
ulation pattern, characteristic for lymphocytes (data not shown). 
These findings are in concordance with the low levels of 
CD3'CD56' N K T cells that were detected in the peripheral blood 
samples of patients with psoriasis by flow cytometric analyses of 
unseparated cells. 
In each experiment controls staining of separated and stimu-
lated T cells was performed after 24 h of culture in medium alone, 
using FITC conjugated anti-CD3 antibodies. The percentage of 
separated cells that expressed the surface molecule CD3 was 
95-98% (data not shown). The vitality of separated and stimu-
lated cells was tested using trypan blue, and was always above 
95%. 
DISCUSSION 
NK T cells are phenolypically and functionally diverse [28]. Ini-
tially, NK T cells were described as cells that express an invariant 
TCR Valphal4 in mouse and Valpha24 in humans [29], Recently 
NK T cells expressing diverse TCRs have been also recognized 
[22,23,30]. The CD3* CD56* cells represent one of these NK T cell 
subpopulations. 
Our results show that the number of CD3+CD56+ NK T cells 
is significantly decreased in the peripheral blood of patients with 
psoriasis and that the percentage of these cells increases after 
different therapies used in psoriasis, but remains significantly 
lower than those found in healthy controls. The full relevance of 
this finding is still speculative. The decrease in the number of 
CD3'CD56* cells may represent an intrinsic characteristic feature 
of patients with psoriasis. This hypothesis is supported by the fact 
that NK T cells do not reach the values found in healthy controls, 
so it is possible that the percentage of this cell population is per-
manently decreased in the peripheral blood of patients with pso-
riasis. Another possible cause that leads to decreased number of 
NK T cells may be represented by the early activation of these 
cells by antigens involved in the relapse of the disease, followed 
by apoptosis [31]. Since we did not study NK T cells in the skin 
we could not exclude that the decrease in NK T cells in the peri-
pheral blood might come from the differential homing of NK T 
cells to the skin lesions. Further studies are needed to elucidate 
the direct role of NK T cells in the skin of patients with psoriasis. 
In our study we found that CD3*CD56* NK T cells were 
capable of rapid activation. After stimulation of CD3' T cells one 
population of activated NK T cells appeared. NK T cells are able 
to recognize non-peplide antigens [32]. In vivo administration of 
synthetic ceramide induces the secretion of both type 1 and type 
2 cytokines [24], but repeated doses polarize NK T cells towards 
Th2 cytokine synthesis [33,34]. Thus IL-4 produced by the NK T 
cells plays a major role in promoting the differentiation of ThO 
cells into Th2 cells [34,35], Although the precise role of NK T cells 
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Fig. 2. Light scatter analysis (FSC versus SSC) of unst imulated peripher-
ial blood CD3* T cells (a) and of separa ted and st imulated CD3* T cells 
(b). Peripheral venous blood sample was obta ined f rom a healthy control. 
Cell separation and st imulation was pe r fo rmed using magnetic beads 
coated with an t i -CD3 monoclonal antibodies. Af te r stimulation of the 
CD3* T cells a distinct populat ion of granulated cells appeared ( R l ) . 
is not yet elucidated, they can be a regulatory cell type playing a 
pivotal role in the development of peripheral tolerance and in the 
modulation of immune responses by inducing a shift in early acti-
vation and consequently in the cytokine secretion of classical T 
cells [36,37]. Psoriasis is an autoimmune disease in which type l 
cytokine secretion pattern can be demonstrated in T cells derived 
from lesional skin and from peripheral blood [8,14]. It is possible 
that this feature is a consequence of an inefficient type 2 response, 
because of lack of NK T cells. This issue might be clarified by 
comparing the IL-4 producing capacity of CD3+CD56+ NK T cells 
from psoriatic patients with that from healty controls. However, 
the study of the cytokine production in psoriasis on a per cell basis 
was beyond the scope of our present work. Our results are the 
first clear-cut evidence showing that low NK T cell counts are a 
characteristic of psoriasis patients.These findings raised the ques-
tion of whether NK T cell deficiency might result in the missing 
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Fig. 3. Phenotypic analyses of separa ted and stimulated CD3* T cells. T 
cells were stained with PE conjugated anl i -CD56 and F I T C conjugated 
anti-CD4. The expression of CD56 and C D 4 surface molecules on granu-
lated CD3* T cells, gate Rl in Fig. 2b and on the less granulated C D 3 T 
cells, gate R2 in Fig. 2a are shown. All the granulated CD3+ T cells express 
the surface molecule C D 5 6 (b, upper left and right quadrants) , but of the 
less granulated CD3* T cells only a minor populat ion express this mole-
cule (a. upper left and right quadrants) . 71-25% of granulated CD3 fCD56* 
cells express the C D 4 marke r (b. upper right quadrant ) , at the same time 
very few (0-58%) of the less granulated T cells express both CD56 and 
C D 4 on the surface (a, uppe r right quadran t ) . 
contraregulatory signals needed for the development of a normal 
immune response upon antigen stimulation, and favours exces-
sive activation of Thl cells. Type 2 cytokines are also important 
in the development of tolerance [38]; thus deficit in these 
cytokines can favour the development of autoimmunity. 
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cells, ga te R2 in Fig. 2a a re shown. 24-4% of g ranu la t ed C D 3 4 C D 5 6 4 cells 
express the C D S m a r k e r (b, u p p e r right q u a d r a n t ) , at the s ame t ime 
11-72% of the less g ranu la ted T cells express bo th C D 5 6 and C D S on the 
surface (a. uppe r right q u a d r a n t ) . 
The dysfunction of NK T cells correlates with the pathogen-
esis of other T cell-mediated autoimmune diseases [39.40], In 
Ipr/lpr mice, in which a spontaneous autoimmune syndrome 
resembling human systemic lupus erythematosus occurs, NK T 
cells disappear from the periphery by the time the autoimmune 
disease develops. Selective experimental depletion of NK T cells 
from the peripheral blood results in early onset and exacerbation 
of the autoimmune phenomena [39]. The selective reduction of 
NK T cells has been also detected in non-obese diabetic mice 
[40,41]. Studies in humans have showed that decreased number 
of NK T cells are present in the peripheral blood of patients with 
rheumatoid arthritis, systemic sclerosis and insulin-dependent 
diabetes mellitus [27,42,43], 
Other lymphocyte populations were also investigated. We 
found no significant differences between total T cells, total B cells, 
T helper cells, T cytotoxic cells and NK cells in patients with pso-
riasis and healthy controls. These results are in concordance with 
observations of other authors and highlight further the signifi-
cance of CD3CD56 4 NK T cells in the pathogenesis of psoriasis 
[44-46], 
We found increased percentage of memory T cells and 
decreased percentage of naive T cells. However, these changes 
were not statistically significant, they might be related to the 
chronic activation of the immune system in patients with psoria-
sis. Increased numbers of memory T cells have been found in 
lesional skin and in the synovial tissue of patients with psoriatic 
arthritis [38,47], It is interesting that the treatments used in this 
study had no effect on memory and naive T cells. It is possible 
that the persistence of the increased number of memory T cells 
is one of the factors that contribute to the relapses observed in 
psoriasis, but these assumptions are still speculative and need 
further investigations. 
In conclusion, our results suggest that CD3fCD56+ NK T cells 
have a role in the pathogenesis of psoriasis and that reduced NK 
T cells can be of importance in the development of psoriasis, a 
Till mediated autoimmune disease. 
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Summary 
2 
It is well known from clinical practice that repeated treatment with dithranol leads to the 
development of tolerance to the drug. In the present study we investigated the characteristics and 
mechanism of dithranol tolerance. The mouse ear was pretreated with a low dose of dithranol or 
croton oil, or on previously sensitised animals by the application of dinitrofluorobenzole (DNFB). 
24 hours later irritative dermatitis was elicited by painting the mouse ear with high dose of 
dithranol, croton oil oil DNFB, and the dermatitis was characterised by measurement of the ear 
thickness. It was shown that low-dose dithranol significantly suppressed dithranol-induced oedema, 
whereas it had no effect on croton oil or DNFB-induced dermatitis, suggesting that dithranol-
induced tolerance is rather specific. Tolerance to dithranol could not be induced by pretreatment of 
the mouse ear with a low dose of croton oil or DNFB. Mild stripping of the mouse ear also inhibited 
the inflammatory effect of dithranol applied 24 hours later. Superoxide dismutase (SOD) treatment 
abolished the tolerance-inducing effect of low-dose dithranol or stripping. These results suggest that 
superoxide anion radicals are involved not only in the inflammatory effect of the drug, but also in 
the induction of dithranol tolerance. 
Key words: dithranol, tolerance, tape stripping, SOD 
Introduction 
3 
Dithranol is one of the most effective local treatment of psoriasis, but its use is hampered by its 
side-effects of irritancy and staining. * In clinical practice, treatment with dithranol is started at low 
concentration in order to prevent severe perilesional inflammation. The concentration of the drug is 
then slowly increased every 2-3 days until mild perilesional irritancy is observed, suggesting that the 
therapeutically effective concentration has been reached. However, after such an "optimal" 
concentration has been found, repeated treatment with the same concentration results within several 
days in a decline of both the irritative but also the antipsoriatic effect. Therefore, to see further 
improvement, the concentration of dithranol should again be increased. This results that, in addition 
to the irritative and staining side-effects of the drug, the adaptation of the skin to dithranol further 
complicates its therapeutic use. 
The antipsoriatic and inflammatory actions of the drug are related probably to its redox 
activity, leading to the production of oxygen r a d i c a l s ; ^ however the mechanism of the increased 
tolerance of the skin to dithranol during repeated treatment is not known. The increased tolerance of 
the skin during the repeated application of dithranol was first proved experimentally by Brandt and 
Mustakallo. They presumed that continuous depletion of the inflammatory mediators of the skin 
resulted in the observed decreased inflammatory effect of the drug.4 In contrast, Lawrence and 
Schuster hypothesised that this phenomenon might be caused by an active adaptive mechanism,^ as 
they found that tape stripping (removing the stratum corneum with an adhesive tape) and 
application of a very low dose of anthralin also induced tolerance of the skin to the drag. We earlier 
studied the effects of repeated dithranol treatment on ear thickness in mice. It was suggested that an 
active adaptation process is responsible for the increased tolerance observed after low-dose 
dithranol treatment. 1 Parslew and Friedmann recently demonstrated that pretreatment of human skin 
with a subirritant concentration of dithranol induced a clear adaptive response, which proved to be 
rather specific as it had no effect on croton oil-induced inflammation. 6 Although these human 
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studies revealed the adaptive response of the skin to dithranol, the underlying mechanisms could not 
be elucidated. 
In the present study, we investigated the characteristics and mechanism of tolerance to 
dithranol in a mouse ear oedema model. Our results suggest that the dithranol-induced increased 
tolerance to the drug is an active process, and oxygen radicals might be responsible for the induction 
of this adaptive response. 
Materials and methods 
5 
Animals 
The animals used were inbred 8-12-week-old male CFLP mice (25-35 g). They were caged in 
groups of 10 and fed on standard mouse pellets and water ad libitum. 
Dithranol pretreatment in dithranol, croton oil and DNFB dermatitis 
Groups of mice were treated by applying 20 pi 0.025% dithranol (Hernial, Reinbek, Germany) or 
acetone to the mouse ear. 24 hours later 20 pi 0.5% dithranol, 5% croton oil (Sigma, St. Louis, 
USA) or 0.15% DNFB (Sigma, St. Louis, USA) in previously DNFB-sensitised animals was applied 
to the mouse ear. Dithranol, croton oil and DNFB were dissolved in acetone. To achieve the DNFB 
sensitisation, the abdominal skin of the animals was shaved and 10 pi 0.2% DNFB dissolved in 
acetone was dropped onto the skin once daily for 2 days. The allergic contact dermatitis was elicited 
3 days later. 
DNFB pretreatment in dithranol and croton oil dermatitis 
Groups of mice were treated with by applying 20 pi 0.05% DNFB or acetone onto the mouse ear on 
previously sensizitised animals. For DNFB sensitisation, 10 pi 0.1% DNFB was dropped to the 
shaved abdominal skin of the animals. In each DNFB and acetone-pretreated mouse group, 20 pi 
0.5% dithranol or 5% croton oil was applied 24 hours later to the mouse ear to generate irritative 
dermatitis. 
Croton oil pretreatment in dithranol, croton oil and DNFB dermatitis 
The mouse ear was treated with 20 pi 0.5% croton oil or acetone,. 24 hours later 20 pi 0.5% 
dithranol, 5% croton oil or 0.15% DNFB (in previously DNFB-sensitised animals) was applied to 
the mouse ear. The DNFB sensitisation procedure was the same as described above. 
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SOD and dithranol pretreatment in dithranol dermatitis 
Two mouse groups received 0.1 ml (20 mg kg"1) Superoxide dismutase (SOD, Griinenthal GmbH, 
Germany) or physiological sodium chloride solution intraperitoneally. One hour later, 20 pi 0.025% 
dithranol or acetone was applied to the mouse ear. Twenty-four hours after the dithranol or acetone 
treatment, inflammation was induced in the mouse ear with 0.5% dithranol. 
The effect of tape stripping in dithranol dermatitis 
Both ears of the mice were covered with adhesive tape, which was removed and applied again 5 
times (stripping). One, 2 or 7 days later, 0.5% dithranol was applied to the mouse ear. Other groups 
of mice received 0.1 ml (20 mg kg"1) SOD intraperitoneally before stripping 
Measurement of mouse ear oedema 
The extent of oedema induced by the skin irritants was characterised by measuring the mouse ear 
thickness with dial gauge. 
Statistical analysis 
Data are presented as the mean + S.D. Student's t-tests were used for analyses comparing the 
different groups, with statistical significance considered if P < 0.05. 
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Results 
Effects of dithranol pretreatment on diihranol, croton oil and DNFB-induced mouse ear oedema 
The ear thicknesses of 0.025% dithranol or acetone pretreated mice were not significantly different 
24 hours after application (19.3 ± 0.7x10"2 mm and 18.9 ± 0.7x10"2 mm, respectively, p>0.05; 
n=30). 
After the mouse ear had been pretreated with 0.025% dithranol for 24 hours, the 0.5% 
dithranol-induced ear thickness was 40% less than that in the acetone treated group. Dithranol 
pretreatment (0.025%) of the mouse ear did not influence the 5% croton oil or 0.15% 
DNFB-induced ear oedema: there was no any significant difference between the ear thicknesses in 
the dithranol or acetone pretreated mice (Fig. 1). Intraperitoneal SOD pretreatment 1 hour before the 
application of 0.025% dithranol eliminated the induction of dithranol tolerance (Table 1). 
Effects of DNFB pretreatment on dithranol and croton oil induced mouse ear oedema 
After 0.1% DNFB senzitization, the ear thicknesses of 0.05% DNFB or acetone pretreated mice 
were not significantly different 24 hours after application (19.2 + 0.9xl0"2 mm and 19.1 ± 0.8xl0"2 
mm, respectively, p>0.05; n=30). 0.05% DNFB pretreatment of the mouse ear for 24 hours did not 
influence the 0.5% dithranol or 5% croton oil-induced ear oedema (Fig. 2). 
Effects of croton oil pretreatment on dithranol, croton oil and DNFB-induced mouse ear oedema 
The ear thicknesses of 0.5% croton oil or acetone pretreated mice is not significantly different 24 
hours after application (19.4 + 0.8xl0"2 mm and 19.1 ± 0.7xl0*2 mm, respectively, p>0.05; n=30). 
0.5% croton oil pretreatment of the mouse ear for 24 hours did not influence the 0.5% dithranol, 5% 
croton oil or 0.15% DNFB-induced ear oedema: there was no significant difference in ear thickness 
between the croton oil or acetone-pretreated mice (Fig. 3). 
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Effects of tape stripping on 0.5% dithranol-induced ear oedema 
The extent of ear oedema in the animals pretreated with dithranol directly after stripping did not 
differ from that in the control group. When dithranol was applied 24 hours after stripping the change 
in oedema was significantly less than that in the control group. Two days after stripping, the 
increase in ear thickness was still less than that in the control group, but stripping did not influence 
the inflammation induced by dithranol applied 7 days later (Table 2). Intraperitoneal SOD 
pretreatment 1 hour before stripping eliminated the inhibitory effect of stripping on the ear thickness 
change observed 24 hours later (Table 3). SOD pretreatment did not affect the inflammatory effect 
of dithranol applied 48 hours after stripping. 
Discussion 
9 
In the present study we could model the tolerance inducing effect of dithranol in mice. Our results 
indicate that pretreatment of the mouse ear with low-dose dithranol concentrations significantly 
decreases the oedema-inducing effect of higher dithranol concentrations applied later, but does not 
effect the extent of croton oil or DNFB dermatitis. This suggests that this type of tolerance is 
specific for dithranol dermatitis. When the mice were pretreated with SOD 1 hour before low-dose 
dithranol pretreatment, the tolerance inducing effect disappeared. As SOD is responsible for the 
elimination of superoxide anion radicals,? it is very likely that free oxygen radicals are involved in 
the induction of dithranol tolerance. We demonstrated that tape stripping induced a tolerance to 
dithranol similar to that following low-dose dithranol pretreatment on the mouse ear, and this 
tolerance could be reduced with an SOD injection 1 hour before stripping. Since SOD cannot 
penetrate the plasma membrane, it exerts its effect on the extracellular space;** it is probable that 
superoxide radicals generated extracellularly are responsible for the tolerance induction. 
It is known from clinical practice that repeated treatment with dithranol leads to a tolerance 
to the drug in the skin. Brandt and Mustakallo presumed that this tolerance is due to the continuous 
depletion of the inflammatory mediators.2* Our results suggest that, even after treatment of the 
mouse ear with croton oil in higher concentrations, the quantity of inflammatory mediators 
remaining in the skin is still sufficient to evoke inflammation. We presume that the dithranol 
induced tolerance of the skin is caused by an an active adaptive mechanism. The superoxide anion 
radicals which are generated extracellularly on the autooxidation of dithranol may be involved in 
triggering this adaptive mechanism, which defends the organism from the toxic action of free 
radicals. 
The studies of Lawrence and Schuster indicated that tape stripping moderates the 
inflammatory effect of dithranol applied 24 hours later, wheras it has no effect on the irritation 
induced by dithranol applied immediately after stripping.^ They supposed that stripping triggers an 
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unknown adaptive mechanism. Our indirect results suggest that superoxide anion radicals generated 
in the skin during tape stripping induce adaptive mechanisms. In the studies by Juhlin^ and Misch et 
al. I® u v irradiation was found to moderate the erythema-generating effect of dithranol applied 24 
hours later. They supposed that UV irradiation induced increased autooxidation of dithranol resulted 
the less inflammatory effect of the drug. However, it is well known that UV irradiation induces free 
radical production in the skin.H»12 We suggest that the inhibitory effect of UV irradiation on 
dithranol dermatitis is also connected with the adaptive mechanism triggered by superoxide anion 
radicals. 
The adaptive adaptive mechanism that eliminates free radicals generated during repeated 
treatment with dithranol is not fully known. Our results indicate that the adaptive response might be 
triggered by the extracellularly localised superoxide anion radicals. Earlier we have shown that in 
dithranol induced inflammation free radicals played an important role^. Free radicals have been 
shown to induce the activity of antioxidant enzymes^, we suppose that one of the extracellular 
antioxidant enzymes might be responsible for the observed adaptive mechanism induced by 
dithranol or tape stripping. The extracellular SOD and thioredoxinreductase are the two important 
extracellular antioxidant enzymes. The activity of the extracellular SOD is very low and probably 
protects only the endothelial cells**, it is unlikely that this enzyme would be responsible for the 
observed protective effect. The intensity of dithranol inflammation is higher in nonlesional skin than 
in the lesions^, and indeed dithranol-induced inflammation occurrs characteristically only in the 
perilesional area. It has been shown that the activity of thioredoxinreductase is much higher in 
psoriatic plaques compared to nonlesional skin*7, suggesting that thioredoxinreductase might be 
responsible for the induction of dithranol tolerance. 
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Effect of SOD plus 0.025% dithranol pretreatment on 0.5% dithranol-induced mouse ear oedema 
Control Dithranol SOD+Dithranol SOD 
Increase in mouse ear thickness 
(x 10"2 mm) 18.9 11.2 18.2 19.1 
±SD 1.34 1.52 1.48 1.46 
p 0.001 ns ns 
Values represent mean + SD, n=20, Student's unpaired t test 
p: significance compared to the control 
ns: non-significant 
SD: standard deviance 
SOD: Superoxide dismutase 
Table 1. 
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Effect of tape stripping on 0.5% dithranol-induced mouse ear oedema 
Days after tape stripping 
Control 0 1 2 7 
Mouse ear thickness 
(x 10"2 mm) 18.9 19.2 11.3 14.5 19.1 
±SD 0.82 1.34 1.55 1.42 1.27 
p ns 0.001 0.05 ns 
Values represent mean + SD, n=20, Student's unpaired t test 
p: significance compared to the control 
ns: non-significant 
SD: standard deviance 
Table 1. 
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Effect of SOD plus tape stripping (TS) pretreatment on 0.5% dithranol-induced mouse ear oedema 
Control TS SOD+TS SOD 
Increase in mouse ear thickness 
(x 10"2 mm) 19.2 12.2 18.8 19.3 
+ SD 1.44 1.31 1.63 1.52 
p 0.001 ns ns 
Values represent mean + SD, n=20, Student's unpaired t test 
p: significance compared to the control 
ns: non-significant 
SD: standard deviance 
SOD: Superoxide dismutase 
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Fig. 1. 
Effects of dithranol pretreatment on dithranol, croton oil and DNFB-induced mouse ear oedema 
0.5% dithranol, 5% croton oil or 0.15% DNFB-induced ear oedema after 0.025% dithranol or 
acetone pretreatment for 24 hours. (Values represent mean + SD, n=20, *p <0.05 significant 
differences between the dithranol or acetone pretreated groups, Student's unpaired t test) 
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• acetone 
• 0.05% DNFB 
Fig. 2. 
Effects of DNFB pretreatment on dithranol and croton oil induced mouse ear oedema 
0.5% dithranol or 5% croton oil-induced ear oedema after 0.05% DNFB or acetone pretreatment for 
24 hours. (Values represent mean + SD, n=20, p >0.05 no significant differences between the DNFB 
or acetone pretreated groups, Student's unpaired t test) 
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Fig. 3. 
Effects of croton oil pretreatment on dithranol, croton oil and DNFB-induced mouse ear oedema 
0.5% dithranol, 5% croton oil or 0.15% DNFB-induced ear oedema after 0.5% croton oil or acetone 
pretreatment for 24 hours. (Values represent mean + SD, n=20, p >0.05 no significant differences 
between the croton oil or acetone pretreated groups, Student's unpaired t test) 
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ABSTRACT Alcohol abuse can precipitate the hyperproliferative skin disease psoriasis vulgaris. 
The mechanism by which alcohol affects this disease is still elusive. So far there are no reports 
describing the effects of metabolites relevant to alcohol metabolism on the growth of human 
keratinocytes. In the present study we examined the effect of ethanol and acetone, which exceeds its 
normal endogenous level in the blood of heavy drinkers, on the proliferation of human 
immortalized keratinocytes (HaCaT cells), which are commonly used as a model to study psoriasis. 
HaCaT cells were incubated for 48 and 72 hours in the presence of different ethanol (2.1375 pM-
1,71 mM) and acetone (6,81 pM-1,36 mM) concentrations and the number of viable cells was 
determined by the MTT assay. The effect of ethanol and acetone on the IL-8 mRNA production and 
on mRNA levels of genes characteristic for proliferating keratinocytes such as a5 integrin, 
keratinocyte growth factor receptor and cyclin D1 was studied by RT-PCR. Our data showed that 
both ethanol and acetone induced the proliferating potential of HaCaT cells. The maximum increase 
was observed at 4,275 pM ethanol and at 13,6 pM acetone concentration. The a5 integrin, 
keratinocyte growth factor receptor and cyclin D1 mRNA levels were higher compared to the 
controls already 0.5 hours after ethanol treatment and 2 hours after acetone treatment of the cells. 
Ethanol and acetone did not alter the IL-8 production of HaCaT cells. Our results suggest that 
ethanol and also acetone enhances the proliferation of human immortalized keratinocytes. The 
stimulatory effect of ethanol and acetone used in physiologically relevant concentrations on human 
keratinocytes may be one of the reasons why psoriasis can be precipitated by alcohol misuse. 
Introduction 
Psoriasis is a common genetically determined skin disorder characterized by epidermal 
hyperproliferation and inflammation. Genetic predisposition is essential but exogenous inducing 
factors are required to precipitate the disease. (1) It is a well known phenomenon that increased 
alcohol consumption leads to an exacerbation or treatment unresponsiveness in psoriasis. (2-8) The 
mechanism by which alcohol affects psoriasis is still elusive. 
Numerous studies indicate that acetone exceeds its normal endogenous level in the blood of heavy 
drinkers (9-12). So far there are no reports about the possible effects of acetone on psoriasis. 
The pathologic features observed in psoriasis are partly caused by the highly elevated amounts of 
stimulatory signals. In psoriasis the regulation for interleukin-8 (IL-8) (13;14) and its type I receptor 
(DL-8RA) (15) is altered. IL-8 is chemotactic for neutrophils (16), T lymphocytes (17) and 
keratinocytes (18). It promotes the proliferation (19) and induces human leukocyte antigen-DR 
(HLA-DR) expression of keratinocytes (20). Several antipsoriatic compounds have inhibitory 
effects on IL-8 binding to cultured keratinocytes (21). 
The epidermal hyperplasia in psoriasis is characterized by an increased percentage of normally 
quiescent basal keratinocytes in the proliferative phases of cell cycle. (22) Progression to the cell 
cycle is regulated by cyclin dependent kinases, which are activated by specifically binding to 
cyclins. (23;24) Keratinocytes express cyclin D1 when they traverse from GO into cell cycle prior to 
Gl. (25) Cyclin D1 is associated with epithelial hyperproliferation (26) and is overexpressed in 
psoriasis. (27;28) Furthermore there is increasing evidence of the therapeutic role of cyclin 
inhibitors in psoriasis. (29;30) 
In addition to cell cycle regulation molecules soluble mitogens such as growth factors and their 
receptors regulate cell growth. 
Keratinocyte growth factor (KGF), a fibroblast-derived member of the fibroblast growth factor 
(FGF) family acts on epithelial cells (31). It has a potent mitogenic activity on human keratinocytes 
and is involved in the control of epithelial proliferation and differentiation (32). KGF binds to the 
tyrosine kinase KGF receptor (KGFR) which is a splicing transcript variant of the fibroblast growth 
factor receptor 2 (FGFR2) (33;34). An increased KGF and KGFR expression, associated with 
lesional psoriatic tissue might play a role in epidermal hyperproliferation in this disease (35). 
Insoluble extracellular molecules play an important role in the regulating the growth of ancorage-
dependent cells. (36-38) 
Integrins are a large family of cellular surface molecules interacting with the extracellular matrix. 
Keratinocyte integrins are important epidermal regulatory molecules, they are involved in adhesion, 
migration, growth and differentiation (39) Fibronectin can regulate keratinocyte growth through the 
fibronectin receptor (a5pl). Alterations in expression, topography and function of integrin 
receptors have been reported in lesional and also in nonlesional psoriatic keratinocytes. (40;41) 
Nonlesional psoriatic skin expresses higher a5 integrin levels relative to normal keratinocytes, 
which may lead to the hyperresponsiveness of psoriatic keratinocytes to proliferation signals 
provided by lymphokines produced by intralesional T lymphocytes. (42) 
HaCaT cells are commonly used as model system to study hyperproliferative skin diseases such as 
psoriasis. (43-48) 
HaCaT keratinocytes are proper candidates for studying external regulators of proliferation and 
differentiation (49). Depending on the in vitro conditions HaCaT cells represent different types of 
keratinocytes. In contact-inhibited, serum-starved culture these cells resemble suprabasal 
nonproliferated differentiated keratinocytes, after release from contact inhibition and the addition of 
serum they resemble the activated, differentiated transiently amplifying keratinocytes. (50) 
In this study we investigated the effects of ethanol and acetone used in physiologically relevant 
concentrations on human HaCaT keratinocytes.We found that both ethanol and acetone exerts a 
proliferative effect on keratinocytes as determined by number of viable cells. In HaCaT cells 
ethanol and acetone did not alter the strong IL-8 mRNA expression but upregulated the mRNA 
levels of cell cycle regulation-related genes: a5 integrin, KGFR and cyclin Dl. These results 
indicate that ethanol and acetone may have a role in precipitating psoriasis. 
Materials and methods 
Cell culture 
The spontaneously transformed human keratinocyte cell line HaCaT (kindly provided by N.E. 
Fusenig, Heidelberg, Germany) was cultured in Dulbecco's modification of Eagle's medium 
(DMEM; Gibco, Eggstein, Germany) containing 10% fetal calf serum (FCS; Gibco), L-glutamine, 
penicillin/streptomycin and fungizone (Sigma, Budapest, Hungary). The cells were maintained at 
37°C in a humid 5% CO2 atmosphere incubator. 
Ethanol and acetone treatment 
The subconfluent cultures were washed with phosphate buffered saline (PBS) under sterile 
conditions and were incubated for 30 minutes at 37°C with increasing concentrations of ethanol 
(2,13 pM -1710 pM) or acetone (6,81 pM -1360 pM) in DMEM containing 0.5% FCS. Control 
cells were incubated in DMEM containing 0.5% FCS for 30 minutes. 
Determination of cell viability 
HaCaT cells were plated at a density of 1x104 cells/well in 96-well microtiter plates. Cells were 
grown to subconfluence. After incubation with different ethanol and acetone concentrations for 30 
minutes in the presence of DMEM containing 0.5% FCS cells were washed with PBS and DMEM 
containing 10% FCS was added to each well. 72 hours after ethanol treatment or 48 hours after 
acetone treatment HaCaT cell viability was measured by the MTT (3-4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide) assay (51) 
RNA extraction and reverse transcriptase polymerase chain reaction (RT-PCR) 
Cells were grown to subconfluence in 6-well plates. After different concentrations of ethanol or 
acetone treatment HaCaT keratinocytes were washed with PBS and were incubated in DMEM 
containing 10% FCS at 37°C in a humid 5% CO2 atmosphere incubator before total cellular RNA 
isolation according to the TRIzol® protocol (Gibco). 
First-strand cDNA was synthesized from 0.5 pg of total RNA in 20 pi final volume (MBI 
Fennentas, Vilnius, Lithuania). After reverse transcription (RT) semiquantitative polymerase chain 
reaction (PCR) was performed using Taq DNA polymerase and dNTP set (MBI Fermentas, Vilnius, 
Lithuania). 2 pi aliquot of the RT solution was used as a template for the p-actin, IL-8, KGFR, 
cyclin Dl, and a5 integrin specific PCR reactions. 
The following primer sequences were used: p-actin: 5'-AGA GAT GGC CAC GGC TGC TT-3' 
and 5'- ATT TGC GGT GGA CGA TGG AG -3', IL-8: 5'-ATG ACT TCC AAG CTG GCC GTG 
GCT-3' and 5'-TCT CAG CCC TCT TCA AAA ACT TCT T-3', KGFR: 5'-AGT TTA AGC AGG 
AGC ATC GCA TT-3' and 5'-CTG TTA CCA CCA TAC AGG CGA TTA A-3', cyclin Dl: 5'-
AGG AGA ACA AAC AGA TCA-3' and 5'-TAG GAC AGG AAG TTG TTG-3', a5: 3'-ATT 
ATC AGA GCA AGA GCC GGA TAG A-5' and 5'-GGA GAT GAG GGA CTG TAA ACC OA-
S' at a final concentration of 0.66 pmol/pl. The following cycling times and temperatures were used 
to amplify the cDNA: P-actin (25 cycles of 94°C for 60 s, 60 °C for 60 s and 72°C for 60 s), IL-8 
(35 cycles of 94°C for 60 s, 59 °C for 90 s and 72°C for 90 s), KGFR (30 cycles of 94°C for 60 s, 60 
°C for 60 s and 72°C for 60 s), cyclin Dl (35 cycles of 94°C for 60 s, 60 °C for 60 s and 72°C for 60 
s), a5 integrin (30 cycles of 94°C for 60 s, 60 °C for 60 s and 72°C for 60 s). After PCR 
amplification products were visualized by EtBr-stained agarose gel electrophoresis. 
Statistical analysis 
Data are presented as the mean ± SEM. Student's t-tests were used for analyses comparing the 
different groups, with statistical significance considered if P < 0.05. 
Results 
HaCaT cells were incubated for 48 and 72 hours in the presence of different ethanol (2.1375 pM-
1,71 mM) and acetone (6,81 pM-1,36 mM) concentrations and the number of viable cells was 
determined by the MTT assay. Our data showed that both ethanol (Fig. 1 ) and acetone (Fig. 2) 
induced the proliferating potential of HaCaT cells. 
The effect of ethanol and acetone on the mRNA levels of genes characteristic for proliferating 
keratinocytes such as a5 integrin, KGFR and cyclin D1 was studied by RT-PCR, a5 integrin, 
KGFR and cyclin D1 mRNA levels were higher compared to the controls already 0.5 hours after the 
ethanol treatment and 2 hours after the acetone treatment of the cells. Ethanol and acetone did not 
alter the IL-8 production of HaCaT cells . (Fig. 3) 
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Fig. 1. Relative changes in the number of viable cells determined by the MTT assay 72 hours after 
ethanol treatment. At 4,27 pM or 8,55 pM concentration ethanol significantly increased the number 
of viable HaCaT cells compared to the control (0 pM ethanol). At 1710 pM concentration ethanol 
proved to be toxic and significantly decreased the number of viable HaCaT cells compared to the 
control (0 pM ethanol). Bars represent means of 3 independent experiments ± SEM, (*p<0,05). 
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Fig. 2. Relative changes in the number of viable cells determined by the MTT assay 48 hours after 
acetone treatment. At 13,6 pM or 136 pM concentration acetone significantly increased the number 
of viable HaCaT cells compared to the control (0 pM acetone). At 1360 pM concentration acetone 
proved to be toxic and significantly decreased the number of viable HaCaT cells compared to the 
control (0 pM acetone). Bars represent means of 3 independent experiments ± SEM, (*p<0,05). 
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Fig. 3. RT-PCR analyses of IL-8 and cell cycle regulation-related genesThe a5 integrin, cyclin D1 
and KGFR mRNA levels were higher compared to the controls after 2 hours of ethanol and 0.5 
hours of acetone treatment of HaCaT cells. Ethanol and acetone did not alter the IL-8 mRNA 
expression of HaCaT cells 
Discussion 
Psoriasis is a one of the commonest inflammatory dermatoses. Genetic predisposition is 
indispensable but exogenous precipitating factors are also required to trigger the disease such as 
trauma, infections, drugs, stress, endocrine and metabolic factors. (1) Alcohol misuse has emerged 
as and additional factor, which may be associated with psoriasis (2-8), but controversy still exists 
over this topic. 
Protein kinase C (PKC) isoenzymes play an important part in signal transmission regulating cellular 
growth, differentation, cytokine production and adhesion molecule expression. In psoriasis down 
regulation of several PKC isoenzymes occurs. In vitro studies show that ethanol can both inhibit or 
enhance PKC activity, depending on the experimental conditions. (52) 
Decreased cyclic AMP (cAMP) levels or an increase in the CGMP/CAMP ratio causes stimulation 
of cell activity. These changes are important in the hyperproliferation associated with psoriasis. (53) 
Acute ethanol exposure increases the amount of cAMP (54-57) and inhibits the accumulation of 
cyclic GMP (58), thus showing an antipsoriatic effect. Chronic alcohol exposure showed opposite 
effects. (59) 
Extracellular lipids of the stratum corneum ere essential for the epidermal permeability barrier 
function, which is an important factor in regulating epidermal DNA synthesis. (60;61) Alterations 
in epidermal lipid content and metabolism have been observed in psoriasis. (62;63) Most of the 
investigations indicate that ethanol enhances cholesterol synthesis, increases the activity of 3-
hydroxy-3-methyl-glutaryl coenzyme A (HMG CoA) reductase, and induces an elevation of 
triglicerides, high-density lipoprotein, and cholesterol levels in serum and liver. (64-67) However 
agents known to induce psoriasis generally inhibit cholesterol synthesis and lipid metabolism. 
Therefore these findings make it very unlikely that effects of ethanol on psoriasis are mediated 
through the above mentioned regulatory systems (1). 
Some studies indicate that alcohol alters the immune system. It is known that alcoholics are more 
susceptible to various infections. (68) Because streptococcal infections are trigger factors for 
psoriasis this increased susceptibility may be involved in the onset and progress of the disease. 
Ockenfels et al. developed a co-culture model with psoriatic keratinocytes and a T-lypmphoma cell 
line (HUT-78). It was found that interleukin-6 (IL-6), transforming-growth-factor-a (TGF-a) and 
interferon-y (IFN-y) levels were elevated in the ethanol-treated psoriatic co-culture system 
indicating an enhanced Th-1 type response in the presence of ethanol. (69) 
Among heavy drinkers blood acetone level is elevated. It is widely accepted that blood acetone 
concentration is good indicator of alcohol consumption. So for there were no reports on possible 
role of blood acetone concentration in evoking psoriasis. 
IL-8 is one of the several proinflammatory mediators that have been reported in lesional skin in 
psoriasis. (70) The induction of the epidermal IL-8 pathway is characterized by the keratinocytic 
overexpression of IL-8 and its receptor CXCR2 in psoriatic lesions. (71;72) The chemoattractive 
properties of keratinocyte-derived IL-8 may contribute to the epidermal accumulation of T cells and 
neutrophils in lesional skin. IL-8 is involved in the stimulation of epidermal cell growth (73) 
induction of major histocompatibility complex class II expression (74) and in the upregulation of the 
inducible nitric oxide synthase (75). In our study we found that ethanol and acetone did not alter the 
strong IL-8 gene expression of HaCaT cells. 
The hallmark of psoriasis is the high epidermal cell turnover. By binding to CDKs, cyclins initiate 
the G0-G1 transition. Cyclin Dl binding with CDK4/6 starts the G1 phase.(23;24) Cyclin Dl is 
associated with epithelial hyperproliferation (26) and is overexpressed in psoriasis. (27;28) Our 
results showed that after ethanol and acetone treatment the ratio of HaCaT cells traversing from GO 
into cell cycle prior to G1 is increased. This is similar in psoriasis where the ratio of cycling cells 
compared to the total number of germinative cells is high. 
Soluble mitogens such as growth factors and their receptors are important in regulating cell growth. 
KGF is a paracrine mediator of epithelial cell growth. (76) KGF elicits its activity through binding 
to the tyrosine kinase KGFR. (33;34) Alterations in the KGF signaling pathway might be involoved 
in the epidermal hyperplasia associated with psoriasis. Increased expression of KGF and KGFR is 
characteristic for lesional psoriatic tissue. (35) Our results demonstrate that KGFR expression in 
HaCaT keratinocytes is upmodulated after ethanol and acetone exposure, thus suggesting an 
increased KGF signaling in our model system. 
Insoluble extracellular molecules also play an important role in the regulating the growth of 
ancorage-dependent cells. (77) 
Integrins are a large family of cellular surface molecules interacting with the extracellular matrix. 
Keratinocyte integrins are important epidermal regulatory molecules, they are involved in adhesion, 
migration, growth and differentation (39) Fibronectin can regulate keratinocyte growth through the 
fibronectin receptor (a5|31). The expression of a5 integrin in HaCaT keratinocytes is related to an 
undifferentiated, intensely proliferating state of these cells indicating that HaCaT cells are 
appropriate to study external regulators of proliferation and the underlying molecular mechanisms 
(50) We observed a strong expression of a5 integrin in ethanol and acetone treated HaCaT cells. 
Alterations in expression, topography and function of integrin receptors have been previously 
reported in lesional and also in nonlesional psoriatic keratinocytes. (40;41;78) It is known that 
nonlesional psoriatic skin expresses higher a5 integrin levels relative to normal keratinocytes, 
which may lead to the hyperresponsiveness of psoriatic keratinocytes to proliferation signals 
provided by lymphokines produced by intralesional T lymphocytes. (42) It is possible that the effect 
ethanol and acetone on a5 integrin expression of HaCaT cells increases their proliferating capacity. 
In the present study we found that, at non-cytotoxic concentrations, ethanol and acetone enhances 
the proliferation of HaCaT cells. Our results also indicate that the effect of ethanol and acetone is 
partly mediated by genes characteristic for proliferating keratinocytes such as a5 integrin, KGFR 
and cyclin D1. Our findings provide further data to understand how alcohol misuse may contribute 
to exacerbating psoriasis. 
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